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Rationale: Although the economic burden of COPD has gained attention in recent years, data
on the costs of COPD among U.S. Medicare beneficiaries are lacking.
Methods: This study used administrative claims and eligibility records from a large U.S. multi-
state Medicare managed care database. Study patients were 65þ years of age with paid claims
during 2004. The COPD cohort comprised patients with 1þ inpatient/ER claims or 2þ outpa-
tient claims (>30 days apart) for COPD (ICD-9-CM codes 491.xx, 492.x, 496). The comparison
cohort included patients without COPD matched 3:1 to the COPD cohort on age, sex, enroll-
ment months, and Medicare plan. Excess costs of COPD were estimated as the difference in
overall health plan payments between the two cohorts during 2004. Attributable costs were
calculated using medical claims with listed diagnoses of COPD or other respiratory-related
conditions and pharmacy claims for respiratory medications.
Results: A total of 8370 patients were included in the COPD cohort and were matched to
25,110 comparison cohort patients. For both groups, mean (SD) age was 78 (8) years, 54% were
female, and duration of eligibility was 11 (2) months. COPD patients were more likely to utilize
healthcare services and had excess total healthcare costs about $20,500 higher (P< 0.0001)
than the comparison cohort. Comorbidities were high in the COPD cohort, accounting for
46% of the observed excess cost. The attributable cost of COPD averaged about $6,300; other
respiratory-related costs averaged about $4,400.nted at the 2007 American Thoracic Society International Conference, San Francisco, California, May
1 290 0808X42; fax: þ1 781 290 0029.
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Costs of COPD in a Medicare population 1249Conclusion: In this U.S. Medicare managed care population, COPD posed a substantial burden
in terms of both respiratory-related and total healthcare costs. A comparison of these cost-of-
illness estimates to those for elderly COPD patients in other countries would be of great inter-
est, given the increasing age of populations in most Western countries.
ª 2008 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is a slow
progressive disease characterized by airflow limitation and
gradual loss of lung function that is not fully reversible.1 It is
estimated that over 12.1millionU.S. adults (4.3%)were diag-
nosed with COPD in 2001 and 24 million overall (8.5%) have
evidence of impaired lung function.2 According to the World
Health Organization (WHO), at present, an estimated 80 mil-
lion people worldwide have moderate to severe COPD.3 The
burden of COPD is increasing and this trend is expected to
continue as the populations of manyWestern countries age.1
The term COPD includes chronic bronchitis and emphy-
sema.4 Symptoms of COPD include cough, sputum produc-
tion, wheezing, and dyspnea, with the latter being the
most prominent and disabling symptom and the most com-
mon reason patients seek medical care.5 Diagnosis is usually
made on the basis of medical history, physical examination,
and results from pulmonary function testing.4 Treatment
options for COPD are largely aimed at symptom control
and reducing acute exacerbations; these include inhaled
and oral bronchodilators, anti-inflammatory drugs, and
supplemental oxygen.4
COPD also poses a substantial economic burden. Several
published studies have evaluated the mean per-patient cost
of COPD from the perspective of national health authorities
or specific payers. Cost estimates are available from the
Confronting COPD Survey for seven major countries.6 For
the U.S., COPD cost information is available for Medicaid
and commercial managed care, while other analyses have
included all payers, using data from national surveys.7e14
However, to the best of our knowledge, only one published
study focused on the cost of COPD among Medicare benefi-
ciaries.8 That study used data that are more than a decade
old, suggesting the need for analyses that reflect current
medical practice.
The objective of the current study was to estimate the
excess costs of COPD for patients enrolled in U.S. Medicare
managed care plans and to place these findings in the context
of international data. In the U.S., over 43 million persons are
enrolled in Medicare, which primarily covers the aged (65
years and older) population, and which enacted a new pro-
gram in 2006 to cover outpatient prescription medications.15
Medicare spending accounts for over 20% of all U.S. national
healthcare expenditures.16Methods
Data source
The PharMetrics Patient-Centric Database was used for this
cross-sectional study. This database contains completehealthcare information for approximately 55 million enroll-
ees from 75 managed care organizations across each of the
U.S. census regions (i.e., Northeast, South, Midwest, West).
In addition, this database contains claims records for
several million Medicare managed care enrollees and
captures drug utilization covered under the health plans.
A standard extract from the PharMetrics database was
provided to us for analysis that included claims details
along with eligibility data.
The claims file contained a number of specific elements
for medical and pharmacy claims. Medical claims captured
details regarding dates of service, place of service (e.g.,
hospital inpatient), physician specialty, up to 4 ICD-9-CM
codes, procedure codes (in CPT-4, HCPCS level II, or
revenue code format), charges, and health plan payments.
Pharmacy claims included details on dispense date, Na-
tional Drug Codes (NDC), quantity of medication dispensed,
days’ supply, and health plan payments. The eligibility file
contained details on monthly medical and pharmacy eligi-
bility, age, sex, and geographical region for individuals who
were present in the claims file.
To ensure completeness of the data, records from
Medicare risk plans that had known carve-outs for Medicare
services (e.g., capitated skilled nursing facility and home
healthcare coverage) were excluded from the final analytic
database.
Patients
All patients were required to be at least 65 years of age as
of January 1, 2004. Medicare beneficiaries were assigned to
one of two study cohorts, as follows:
COPD cohort
Patients were eligible for the COPD cohort if they: (1) had 1
or more inpatient or emergency room claims, or 2 or more
outpatient claims (separated in time by at least 30 days),
with any listed diagnosis of COPD (ICD-9-CM codes 491.xx,
492.x, or 496) during 2004; and (2) were eligible for medical
and pharmacy benefits in the Medicare risk plan during the
month(s) of their COPD claim(s).
Comparison cohort
Patients were candidates for inclusion in the comparison
cohort if they: (1) had no claims with a listed diagnosis of
COPD in 2004, but had 1 or more medical claims with a valid
ICD-9-CM diagnosis code for any other condition; and (2)
were eligible for medical and pharmacy benefits in the
Medicare risk plan during themonth of their non-COPD claim.
Each COPD patient was matched to 3 patients from the
comparison cohort based on age (within 2 years), sex,
months of enrollment during 2004 (within 2 months),
and the specific Medicare risk plan. One patient was
1250 J. Menzin et al.randomly selected from the comparison cohort pool if more
than 3 eligible matches were available for that COPD case.
Study measures
Excess healthcare utilization and cost
We evaluated the use of healthcare services and medica-
tions among the COPD and comparison cohorts without
regard to diagnosis (i.e., as ‘‘all-cause’’). Expenditures byTable 1 Characteristics and comorbid conditions for COPD and
Measure COPD cohort nZ
Agea:
65e74 years (%) 34.6
75e84 years (%) 48.6
85þ years (%) 16.9
Mean SD 78.1 (7.5)
Median 77.0
Gendera (%):
Male (%) 45.7
Female (%) 54.3
Region (%):
East 28.9
South 29.1
Midwest 20.7
West 21.3
Number of months of eligibilitya:
Mean SD 11.2 (2.1)
Median 12.0
Selected respiratory conditions (%):
Cystic fibrosis 0.0
Tuberculosis 0.0
Lung cancer 6.5
Concomitant asthma (%): 20.7
Charlson comorbidities (%):
Myocardial infarction 9.5
Congestive heart failure 34.6
Peripheral vascular disease 11.1
Cerebrovascular disease 19.7
Dementia 3.8
Rheumatologic disease 3.5
Peptic ulcer disease 3.0
Mild liver disease 0.8
Diabetes without chronic complications 24.2
Diabetes with chronic complications 2.5
Hemiplegia or paraplegia 0.4
Renal disease 9.3
Any malignancy 22.0
Moderate or severe liver disease 0.3
Metastatic solid tumor 5.0
AIDS 0.1
Source: PharMetrics database 2004.
a Patient characteristics employed in the matching process.the health plan (our measure of costs from the insurer
perspective) were analyzed similarly. Excess costs were
estimated as the paired difference in cost (i.e., between
the COPD and matched comparison cohorts).
Attributable healthcare utilization and cost
Attributable healthcare resource use and costs were ana-
lyzed for the COPD cohort based on specified diagnoses and
prescription drugs. COPD-related medical services werematched comparison cohorts
8370 Comparison cohort nZ 25,110 P-value
34.6 N/A
48.9 N/A
16.5 N/A
78.1 (7.5) N/A
77.0 N/A
45.7 N/A
54.3 N/A
28.9 N/A
29.1 N/A
20.7 N/A
21.3 N/A
11.2 (2.1) N/A
12.0 N/A
0.0 N/A
0.0 N/A
0.6 <0.0001
2.1 <0.0001
2.9 <0.0001
7.6 <0.0001
4.0 <0.0001
9.9 <0.0001
2.2 <0.0001
2.1 <0.0001
1.1 <0.0001
0.4 <0.0001
19.9 <0.0001
1.7 <0.0001
0.2 0.0008
3.7 <0.0001
12.7 <0.0001
0.2 0.0112
1.8 <0.0001
0.0 0.0850
Costs of COPD in a Medicare population 1251required to have ICD-9-CM codes 491.xx, 492.x, or 496
listed as a primary diagnosis on an inpatient claim, or as
a primary or secondary diagnosis on an outpatient claim.
We considered the following types of drugs to be attribut-
able to COPD: antibiotics and oral steroids given within 7
days of a COPD medical claim; short-acting beta-agonists;
maintenance medications, including anticholinergics,
inhaled steroids, long-acting beta-agonists, inhaled combi-
nation therapies, xanthines; and leukotriene antagonists.
The attributable cost of COPD was calculated as the sum of
all amounts paid by the health plan for medical services and
drugs listed above.
For completeness, we also reported other respiratory-
related medical services among patients with COPD
based on having ICD-9-CM codes 460e490, 493.xe495.x,
or 500e519.x listed as a primary diagnosis on an inpatientTable 2 Healthcare utilization for COPD and comparison cohor
Measure COPD co
Inpatient
Overall hospitalizations
Percent with one or more overall hospitalizations 55.7
Mean (SD) number of overall hospital stays 1.1 (1.6
Mean (SD) number of overall hospital days 8.9 (17.
Skilled nursing facilities (SNFs)
Percent with one or more SNF stays 9.6
Mean (SD) number of SNF stays 0.1 (0.5
Mean (SD) number of SNF days 1.6 (8.3
Outpatient
Hospital outpatient (HO) services
Percent with one or more HO services 58.4
Mean (SD) number of HO services 3.7 (8.4
Home healthcare (HHC) services
Percent with one or more HHC services 43.4
Mean (SD) number of HHC services 3.8 (8.5
Laboratory tests and procedures
Percent using laboratory tests and procedures 63.0
Mean (SD) number of laboratory tests
and procedures
1.5 (2.9
Durable medical equipment (DME)
Percent with one or more DME services 12.9
Mean (SD) number of DME services 1.2 (4.5
Emergency room (ER) visits
Percent with one or more ER visits 41.1
Mean (SD) number of ER visits 0.5 (1.1
Physician visits
Pulmonologist
Percent with one or more pulmonologist visits 47.4
Mean (SD) number of pulmonologist visits 3.9 (7.6
Primary care
Percent with one or more primary care visits 37.7
Mean ( SD) number of primary care visits 4.2 (9.1
Overall physician visits
Percent with one or more physician visits 91.7
Mean (SD) number of physician visits 9.2 (9.0
Source: PharMetrics database 2004.claim, or as a primary or secondary diagnosis on an
outpatient claim (as long as COPD was not listed on the
same claim).Data analyses
Descriptive analyses of patient characteristics were per-
formed for the COPD and comparison cohorts, including
demographics, number of months of eligibility, and comor-
bidities. Medical claims were reviewed to assess the
prevalence of comorbidities. A total of 17 binary variables
were created, each corresponding to a chronic disease
contained in the comorbidity scale developed by Charlson
and colleagues.17 The method of Deyo et al., which estab-
lished ICD-9-CM codes for each of these 17 conditions,18ts, by component
hort (nZ 8370) Comparison cohort (nZ 25,110) P-value
14.3 <0.0001
) 0.2 (0.7) <0.0001
6) 1.5 (6.5) <0.0001
2.1 <0.0001
) 0.0 (0.2) <0.0001
) 0.4 (4.0) <0.0001
41.3 <0.0001
) 1.9 (6.4) <0.0001
13.2 <0.0001
) 0.6 (4.0) <0.0001
58.4 <0.0001
) 1.1 (2.2) <0.0001
2.1 <0.0001
) 0.1 (0.8) <0.0001
17.6 <0.0001
) 0.2 (0.6) <0.0001
4.0 <0.0001
) 0.2 (1.4) <0.0001
28.4 <0.0001
) 2.4 (6.3) <0.0001
85.0 <0.0001
) 5.5 (6.7) <0.0001
1252 J. Menzin et al.was used to create the binary comorbidity variables from
the claims database. Finally, these conditions were
weighted to create a single comorbidity score.17 Chronic
pulmonary disease was excluded from calculations of the
comorbidity score as COPD was the disease of interest for
this study.
Healthcare resource utilization and costs were reported
descriptively by component for both cohorts, with excess
costs calculated as the paired difference in costs between
COPD patients and the matched comparison cohort. For the
latter group, we used an average of the values for the 3
comparison group patients who were matched to each
COPD patients. P-values were calculated for resource useTable 3 Pharmacy utilization for COPD and matched compariso
Measure COPD c
Pharmacy
Acute medications (within 7 days of COPD claim)
Oral corticosteroids
Percent with one or more medications dispensed 18.0
Mean (SD) number of medications dispensed 0.4 (1
Antibiotics
Percent with one or more medications dispensed 25.2
Mean (SD) number of medications dispensed 0.4 (0
Rescue medications
Short-acting beta-agonistsa
Percent with one or more medications dispensed 35.4
Mean (SD) number of medications dispensed 1.8 (4
Maintenance medications
Anticholinergics
Percent with one or more medications dispensed 10.7
Mean (SD) number of medications dispensed 0.5 (1
Inhaled corticosteroids
Percent with one or more medications dispensed 7.2
Mean (SD) number of medications dispensed 0.2 (1
Long-acting beta-agonists
Percent with one or more medications dispensed 3.4
Mean (SD) number of medications dispensed 0.1 (0
Respiratory inhalant combinations
Percent with one or more medications dispensed 15.7
Mean (SD) number of medications dispensed 0.6 (2
Xanthines
Percent with one or more medications dispensed 4.5
Mean (SD) number of medications dispensed 0.3 (1
Any maintenance medication
Percent with one or more medications dispensed 29.1
Mean (SD) number of medications dispensed 1.7 (4
Leucotriene antagonists
Percent with one or more medications dispensed 4.0
Mean (SD) number of medications dispensed 0.2 (1
Other medications
Percent with other medications dispensed 77.5
Mean (SD) number of other medications dispensed 24.1 (2
Source: PharMetrics database 2004.
a Includes inhaled and oral formulations.measures based on chi-square and Student t-tests. Log
transformations of the paired difference (COPD vs. compar-
ison cohort) in costs were not performed since the data
curve appeared fairly bell-shaped upon visual inspection.
Multivariate analyses (least-squares means) were per-
formed to determine excess healthcare costs while adjust-
ing for potential differences in months of eligibility,
presence of concomitant asthma, and Charlson comorbidity
scores. Attributable costs of COPD and other respiratory-
related healthcare utilization and costs were evaluated
descriptively by component for COPD patients. All data
analyses were conducted using the Statistical Analysis (SAS)
software package, version 9 (SAS Institute, Cary, NC).n cohorts, by drug type
ohort (nZ 8370) Comparison cohort (nZ 25,110) P-value
0.0 N/A
.1) 0.0 (0.0) N/A
0.0 N/A
.9) 0.0 (0.0) N/A
2.6 <0.0001
.1) 0.1 (0.5) <0.0001
0.2 <0.0001
.8) 0.0 (0.1) <0.0001
0.4 <0.0001
.1) 0.0 (0.2) <0.0001
0.1 <0.0001
.9) 0.0 (0.2) <0.0001
0.7 <0.0001
.0) 0.0 (0.3) <0.0001
0.1 <0.0001
.6) 0.0 (0.3) <0.0001
1.3 <0.0001
.1) 0.0 (0.6) <0.0001
0.4 <0.0001
.1) 0.0 (0.3) <0.0001
70.7 <0.0001
7.6) 16.9 (21.7) <0.0001
Table 5 Adjusted results for excess costs controlling for
eligibility, concomitant asthma, and comorbidity
Variablea Parameter estimate
(U.S. dollars)
t-value P-value
Intercept 11,125 (588) 18.94 <0.0001
Months eligible 2623 (1302) 2.01 0.0440
Asthma 3153 (1200) 2.63 0.0086
Comorbidity 7824 (194) 40.34 <0.0001
a Dependent variable was paired difference in cost (COPD
minus comparison cohort).
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Patient characteristics
A total of 8,370 patients met the selection criteria for the
COPD cohort (Table 1) with 25,110 included in the
matched comparison cohort. The mean (SD) age was
78.1 (7.5) years and 54% were female. COPD patients
had a significantly higher prevalence of several comor-
bidities, including congestive heart failure, vascular
disease, diabetes, renal disease, and cancer. Approxi-
mately 20% of these patients also had a diagnosis of con-
comitant asthma (Table 1). Mean (SD) comorbidity
scores were 2.1 (2.8) and 1.0 (1.6) in the COPD and
comparison cohorts, respectively.
Excess healthcare utilization and cost
The proportion of patients who were hospitalized, visited
an emergency room, or utilized home healthcare services
or durable medical equipment was significantly higher in
the COPD cohort than the comparison cohort (Table 2).
Approximately 56% of patients in the COPD cohort were
hospitalized vs. 14% of those in the comparison cohort. In
addition, approximately 18% and 25% of patients with
COPD used oral steroids and antibiotics within 7 days of
a COPD claim, respectively. Patients with COPD also were
significantly more likely to be prescribed medications, es-
pecially short-acting beta-agonists (35.4 vs. 2.6%), anticho-
linergics (10.7 vs. 0.2%), and respiratory inhalant
combinations (15.7 vs. 0.7%) (Table 3). It is noteworthy,
however, that only 29% of COPD patients received a respira-
tory maintenance medication during 2004.
Mean total healthcare costs were approximately
$20,500 higher in the COPD cohort vs. the comparison
cohort (Table 4); about 80% of this difference is accountedTable 4 Healthcare costs (mean SD) for COPD and matched c
Measure COPD cohort, nZ 8370 (
Inpatient
Hospitalizations 19,270 (44,851)
SNF 720 (3810)
Subtotal 19,991 (45,773)
Outpatient
Hospital outpatient 1661 (6349)
Home healthcare services 590 (1660)
Durable medical equipment 89 (492)
Laboratory tests and procedures 159 (357)
Subtotal 2498 (6682)
Emergency room 502 (1243)
Physician 867 (2485)
Pharmacy 1602 (4716)
Other healthcare costa 2197 (6792)
Total healthcare cost 27,656 (49,199)
Source: PharMetrics database 2004.
Note: Sample size for comparison cohort based on mean of 3 control
a Includes other office visits (e.g., nurse practitioners, physician asfor by excess expenditures on inpatient services. After
adjusting for the burden of concomitant asthma and other
comorbidities (using the Charlson score), as well as the
duration of eligibility, costs were estimated to be
$11,125 higher for the COPD cohort vs. the comparison co-
hort (Table 5). Comorbidities accounted for approximately
46% of the excess cost.
Attributable healthcare utilization and cost
During 2004, COPD patients had substantial use of services
for either COPD or other respiratory conditions. For
example, approximately 47% of COPD patients had hospi-
talizations, 26% had emergency room visits, and 27% used
home healthcare services (Table 6). Almost 60% of COPD
patients visited a pulmonologist. The attributable costs of
COPD averaged approximately $6,300, while other respira-
tory-related costs averaged $4,400.
Discussion
This retrospective database analysis sought to document the
difference in healthcare utilization and expendituresomparison cohorts, by component
U.S. dollars) Comparison cohort, nZ 8370 (U.S. dollars)
3436 (9174)
144 (933)
3580 (9393)
770 (2013)
77 (337)
8 (111)
115 (187)
969 (2091)
167 (425)
472 (816)
860 (1919)
1077 (2653)
7126 (11,242)
s.
sistants) and transportation services (e.g., ambulance).
Table 6 Attributable healthcare utilization for COPD patients
Measure COPDa Other respiratory conditionsb
Inpatient
Hospitalizations
Percent with one or more hospitalizations 27.3 19.6
Mean (SD) number of hospital stays 0.4 (0.8) 0.3 (0.7)
Mean (SD) number of hospital days 3.0 (9.0) 1.7 (6.7)
Skilled nursing facilities (SNFs)
Percent with one ore more SNF stays 0.9 0.5
Mean (SD) number of SNF stays 0.0 (0.1) 0.0 (0.1)
Mean (SD) number of SNF days 0.1 (2.3) 0.1 (1.3)
Emergency room (ER) visits
Percent with one or more ER visits 16.3 10.0
Mean (SD) number of ER visits 0.9 (4.2) 0.5 (3.0)
Outpatient
Hospital outpatient (HO) services
Percent with one or more HO services 20.8 14.4
Mean (SD) number of HO services 1.3 (4.7) 0.6 (2.9)
Home healthcare (HHC) services
Percent with one or more HHC services 22.0 4.8
Mean (SD) number of HHC services 3.7 (9.6) 0.5 (3.6)
Laboratory tests and procedures
Percent using laboratory tests and procedures 11.3 6.2
Mean (SD) number of laboratory tests and procedures 0.4 (1.9) 0.2 (1.4)
Durable medical equipment (DME)
Percent with one or more DME services 8.1 1.5
Mean (SD) number of DME services 1.4 (6.4) 0.2 (1.7)
Physician visits
Pulmonologist
Percent with one or more pulmonologist visits 36.3 22.6
Mean (SD) number of pulmonologist visits 3.8 (9.2) 1.9 (6.9)
Primary care
Percent with one or more primary care visits 21.3 13.7
Mean (SD) number of primary care visits 1.8 (6.1) 0.7 (3.1)
Overall physician visits
Percent with one or more physician visits 61.7 37.0
Mean (SD) number of physician visits 2.6 (5.1) 1.3 (8.7)
Source: PharMetrics database 2004.
a Defined as having a primary ICD-9-CM diagnosis code of 491.xx, 492.x, or 496.
b Defined as having a primary ICD-9-CM diagnosis code of 460e490, 493.xe495.x, or 500e519.x.
1254 J. Menzin et al.between patients with and without COPD enrolled in U.S.
Medicare managed care plans. We found that the per-patient
cost of COPD ranged from $6,300 using an attributable
(COPD-related) cost approach to $20,500 using an excess
cost approach. When excess costs were adjusted for comor-
bidities and other factors, average per-patient costs were
$11,125 higher among COPD patients. A substantial portion of
the costs of COPD is accounted for by inpatient stays.
From the standpoint of Medicare managed care, the
excess costs of COPD are substantial. A recent review of
U.S. cost studies found that those conducted since 2000
showed a range of excess costs from about $6,100 to
$6,600, and attributable costs from $2,700 to $5,900.19
Our estimates of both excess and attributable costs are
somewhat higher than the recent literature. One mightexpect higher costs among Medicare beneficiaries vs. youn-
ger patients enrolled in managed care plans or the general
population of COPD patients.
The Confronting COPD Survey estimated costs for seven
countries and found that annual direct medical costs per
patient ($US 2002) were lowest in France ($522) and the
Netherlands ($606) and highest for Spain ($3,196) and the
U.S. ($4,119).6 Another study in Spain, which included
patients identified from 286 general practices, found that
direct annual costs averaged $1,876.20 Other COPD cost-
of-illness studies evaluated data for patients experiencing
exacerbations of disease21e23 and, therefore, are not di-
rectly comparable to the population-based estimates cited
above. Published worldwide literature on the costs of
COPD, despite varying methodologies, suggests that the
Costs of COPD in a Medicare population 1255per-patient direct costs in many countries are substantial.
COPD costs appear to be highest in the U.S. and particularly
so among the elderly, as shown in this study. Additional
estimates of the cost of this disease among elderly popula-
tions in other countries would be of great interest, given
current demographic trends.
This study is strengthened by the use of two alternative
cost estimation methods. The attributable cost approach
included only medical services that had a coded diagnosis
of COPD. Since most COPD patients have multiple comor-
bidities, in some cases those conditions may be recorded
rather than COPD, which can result in an underestimation
of costs attributable to COPD. This phenomenon may be
especially problematic in the area of physician services, as
many claims databases record only one diagnosis.
The excess cost method measures the overall difference
in expenditures, regardless of diagnosis, for a cohort of
patients with COPD and a comparison group of non-COPD
patients matched on sociodemographic factors. For exam-
ple, we found a higher prevalence of other smoking-related
illnesses (e.g., cardiovascular disease, stroke, and cancer)
in the COPD cohort. Comorbidity burden, as reflected in the
Charlson score, was estimated to account for 46% of the
observed difference in unadjusted excess costs. Because
both cost estimation approaches have merit, we elected to
report both here.
Our study found that approximately 29% of COPD
patients received a respiratory disease maintenance med-
ication during 2004. This rate appears to be low relative to
other published studies, although we acknowledge that
there are limited population-based estimates to confirm
usage of maintenance medication. A Swedish study by
Jansson and colleagues24 found that the average number
of drugs received per patient was 1.05, which may suggest
a fairly high use. In an Italian study25 of recently hospital-
ized patients with 3.4 acute exacerbations in the prior
year, pre-hospital use of long-acting beta-2 adrenoceptor
antagonists was 43%, while 51% received inhaled corticoste-
roids, and 17% received anticholinergics. However, another
Italian study,26 one conducted in a general practice setting,
found that almost half (48%) of subjects with COPD were
not treated with any respiratory drug, including short-
acting beta-2-agonists. It is not clear whether the apparent
low rate of drug use in our study reflects the cross-sectional
nature of the study design, mild disease severity, or the ex-
tent of coverage for respiratory drugs in the health plans.
Further studies of drug treatment patterns for patients
with COPD would be useful.
There are several limitations to our study. First, the
database includes patients enrolled in Medicare managed
care plans rather than all Medicare beneficiaries. Our
findings, therefore, cannot be generalized to the overall
Medicare program. Although a large proportion (approxi-
mately 85%) of Medicare beneficiaries are covered by the
fee-for-service programs, enrollment in Medicare managed
care plans is increasing.27 Second, this analysis used health
insurance claims data, and medical charts were not avail-
able to confirm COPD diagnoses. The use of ICD-9-CM codes
to assess prevalent cases of COPD has not, to our knowl-
edge, been validated against objective clinical data. Third,
this work did not account for patient out-of-pocket ex-
penses in terms of cost sharing or for services not coveredby health plans. Therefore, from a societal perspective,
this study underestimates the per-patient burden of
COPD. Finally, this study does not directly address the ag-
gregate burden of COPD from a national perspective. Addi-
tional studies that evaluate the comparative national and
international economic burden of COPD would be of great
interest.
In summary, we found that the per-patient direct costs
of COPD for U.S. Medicare beneficiaries enrolled in man-
aged care are substantial. A comparison of these cost-of-
illness estimates with elderly COPD patients in other
countries would be of great interest, given the increasing
age of populations in most Western countries.Acknowledgments
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